pharmaphorum

MARCH 7, 2022

A new company set up to use machine learning to find new anti-infective drugs – ArrePath – has launched onto the scene with $20 million in seed financing from a group of investors including the Boehringer Ingelheim Venture Fund. The Princeton, New Jersey-based startup will use the funding to develop its artificial intelligence and imaging based drug discovery platform, used to identify compounds with new and under-exploited mechanisms of action.

Compounding 132

Compounding 132

Pharma Times

MARCH 11, 2022

93% of people suspected by GPs to have cancer should be seen by a specialist within two weeks but this has fallen to just 75%

118

118

Drug Channels

MARCH 8, 2022

Next week, Drug Channels Institute will release our 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 13th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. The exhibit below—one of 216 in our new report—provides a first look at the 15 largest organizations, ranked by total U.S. prescription dispensing revenues for calendar year 2021.

Drug Pricing 84

Drug Pricing 84

NY Times

MARCH 6, 2022

The treatment could be lifesaving for many who cannot get protection from the vaccine, but confusion about the drug has made some doctors slow to prescribe it.

Vaccines 89

Vaccines Immunity Immunization 89

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 11, 2022

A consortium led by the Digital Medicine Society (DiMe) has been set up to try to end inequities in access to clinical trials, focusing on the increasing number of studies that use digital devices to allow participation. The organisation has teamed up with drugmakers GlaxoSmithKline and Amgen as well as partners in the clinical research, patient engagement and data analytics sector on a project to develop the principles that can be used to make sure trials are designed from the ground up to allo

107

107

Pharma Times

MARCH 9, 2022

Trodelvy is accepted for use in mTNBC patients who have already received two or more systemic therapies

122

122

Drug Channels

MARCH 11, 2022

Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. Stacey analyzes trends in patient support services and reimbursement hubs. Learn more about AssistRx’s specialty therapy initiation and patient support services at Asembia's Specialty Pharmacy Summit on May 2-5, 2022. Click here to schedule your meeting.

Specialty Pharmacies 73

Specialty Pharmacies 73

pharmaphorum

MARCH 10, 2022

Mallinckrodt’s liability problems in the US have been lightened slightly, after it agreed a $260 million deal to resolve allegations of Medicare rebate fraud and payment of illegal kickbacks. The Ireland-domiciled company was accused of illegally paying smaller drug rebates to Medicaid than were due, as well as using a charitable foundation to cover co-pays for its Acthar Gel (corticotropin) epilepsy treatment – which is not allowed under US law.

Drug Pricing 101

Drug Pricing Pharmaceutical Manufacturing 101

Pharma Times

MARCH 7, 2022

Fully-automated molecular system with small footprint provides greater flexibility for laboratories without much space

114

114

NY Times

MARCH 8, 2022

A legal battle in Oklahoma over whether prisoners feel severe pain after being given the sedative, midazolam, will determine whether its use is constitutional.

71

71

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Drug Patent Watch

MARCH 11, 2022

Annual Drug Patent Expirations for MAVYRET Mavyret is a drug marketed by Abbvie Inc and is included in two NDAs. It is available from one supplier. There are seven patents…. The post New patent for Abbvie Inc drug MAVYRET appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

MARCH 10, 2022

18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted medicines into clinical trials. The Netherlands-based biotech, which is putting together a pipeline of genetic modifier drugs for cancer and rare diseases, said the new funding would also allow it to double its headcount to add clinical capabilities and move to a larger facility.

Immunity 98

Immunity Immunization 98

Pharma Times

MARCH 10, 2022

Certain areas in the UK have been experiencing a significant increase in COVID-19 cases in recent days

117

117

Pharma Mirror

MARCH 11, 2022

As we get older, it becomes more challenging to take care of our bodies. Injuries, aches, and pains are more likely to occur. To combat aging, it’s smart to invest in your physical health. One of the primary ways that people stay healthy in California is by receiving chiropractic care. A chiropractor in Solana Beach CA can help you maintain your health while avoiding future injuries.

52

52

Drug Patent Watch

MARCH 10, 2022

Annual Drug Patent Expirations for JORNAY+PM Jornay Pm is a drug marketed by Ironshore Pharms and is included in one NDA. There are thirteen patents protecting this drug. JORNAY PM…. The post New patent for Ironshore Pharms drug JORNAY PM appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . Vaccines are a powerful tool and crucial part of fighting diseases, such as tetanus, measles, meningitis, and, recently, COVID-19.

Vaccines 97

Vaccines 97

Pharma Times

MARCH 11, 2022

Treatment demonstrated a good safety profile in the overall patient population during the 12-week induction phase

104

104

Pharma Mirror

MARCH 11, 2022

Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers Tokyo: CPhI Japan 2022 returns as a SMART event – with live exhibition at the Big Sight Exhibition Center in Tokyo (20-22 April) alongside an online networking platform – as CPhI data[1] confirms the country continues to top global ‘API quality’ rankings, with Japanese respondents bullish on growth in 2022 forecasting a CAGR of 14% on average.

52

52

Drug Patent Watch

MARCH 10, 2022

Annual Drug Patent Expirations for GILOTRIF Gilotrif is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Boehringer Ingelheim drug GILOTRIF appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

MARCH 9, 2022

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate can revitalise the franchise. New phase 3 data on efanesoctocog alfa (also known as BIVV001) has met its objectives in a phase 3 study, providing protection from bleeding episodes in patients with haemophilia A with once-weekly dosing.

Labelling 96

Labelling 96

Pharma Times

MARCH 10, 2022

The government’s planned ‘Road to Recovery’ will have a new focus on prevention

107

107

Pharma Mirror

MARCH 11, 2022

Casimir Further Differentiates Emmes’ Industry-Leading Rare Disease Research Capabilities Rockville, MD, March 10, 2022 – Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Casimir, a U.S.-based CRO. Casimir has experience in more than 20 rare diseases and has worked with regulators, sponsors and patients to develop outcome measures that capture the nuan

52

52

illuminate.health

MARCH 10, 2022

Trying to self-manage complex medication regimens can be overwhelming for patients and affect their medication adherence. Now add in high co-pays that prevent patients from accessing their prescribed medications and you have further complicated an already complex situation. With drug manufacturers developing new and innovative medications to treat chronic diseases, it’s estimated that 65% of newly launched medicines within the next 4 years will be specialty medications (1).

52

52

pharmaphorum

MARCH 6, 2022

As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises “substantial doubt” about its ability to continue as a going concern. The biotech is sitting on around $442 million in liquid assets, but is expecting its cash burn in 2022 to be around $400 million, having recorded a net operating loss of $563 million last year.

96

96

Pharma Times

MARCH 8, 2022

Novartis and Voyager Therapeutics announce partnership to develop gene therapies for neurological disorders

102

102

Pharma Mirror

MARCH 11, 2022

The healthcare professions are rewarding, stimulating, prestigious, and lucrative. Few other professionals can say that their daily task is to save lives. The post Common Risks of Working as a Healthcare Professional appeared first on Pharma Mirror Magazine.

52

52

Drug Patent Watch

MARCH 9, 2022

Annual Drug Patent Expirations for SYNDROS Syndros is a drug marketed by Benuvia and is included in one NDA. There are three patents protecting this drug and two Paragraph IV…. The post New patent for Benuvia drug SYNDROS appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

MARCH 8, 2022

To celebrate International Women’s Day, we speak to design engineer at Envair Technology Darina Shopova; managing director, UK & ROI at Healthcare Business of Merck Doina Ionescu; and vice president of clinical development, medical, and regulatory affairs, Novo Nordisk UK Avideh Nazeri about their careers, how their field is progressing and how the industry can encourage more women and girls to pursue roles in STEM.

Hospitals 95

Hospitals Pharmaceutical Manufacturing Communication 95

Pharma Times

MARCH 7, 2022

Largest unmet need in cardiovascular medicine finally receives approved therapy

116

116

Citus Health Specialty Pharmacy

MARCH 9, 2022

In this Voices interview, Hospice News sits down with Melissa Kozak, Co-founder and President of CitusHealth, to learn the next level of family engagement through technology in hospice care. She also shares why, now more than ever, the care staff must be connected — and how technology can help. Read the full interview here The post Next level of family engagement through technology in hospice care appeared first on CitusHealth - digital platform for home-based care providers.

52

52

Drug Patent Watch

MARCH 9, 2022

Annual Drug Patent Expirations for MAVYRET Mavyret is a drug marketed by Abbvie Inc and is included in two NDAs. It is available from one supplier. There are seven patents…. The post New patent for Abbvie Inc drug MAVYRET appeared first on DrugPatentWatch - Make Better Decisions.

52

52

pharmaphorum

MARCH 10, 2022

In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Yet, despite the immense potential of the field, biologics have remained largely untapped. Now, amid a wave of innovation, investors and drugmakers are putting their weight behind the drug class. “Biologics have revolutionised treatments for several serious diseases, some of which had no therapeutic alternatives until now,” says Antonio Magnelli, head of the Chiesi

Pharmaceutical Companies 94

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunity 94

Pharma Times

MARCH 9, 2022

Results showed a clinically meaningful prevention of bleeds in people with severe haemophilia A

103

103

Pharma in Brief

MARCH 9, 2022

The Federal Court has decided an infringement action concerning risedronate products under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). The Court dismissed allegations of anticipation based on prior art, as well as arguments that the asserted claims were invalid due to lack of demonstrated utility, insufficiency of disclosure, and/or overbreadth.

Dosage 52

Dosage Pharmaceutical Companies Pharmaceutical Companies 52

Drug Patent Watch

MARCH 8, 2022

Annual Drug Patent Expirations for LEQVIO Leqvio is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are nineteen patents protecting…. The post New patent expiration for Novartis drug LEQVIO appeared first on DrugPatentWatch - Make Better Decisions.

52

52